Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study

Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration. The exact mechanisms leading to this rapid effect have not...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mult Scler
Hlavní autoři: Hagens, Marloes HJ, Killestein, Joep, Yaqub, Maqsood M, van Dongen, Guus AMS, Lammertsma, Adriaan A, Barkhof, Frederik, van Berckel, Bart NM
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2017
Témata:
Short Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891689/
https://ncbi.nlm.nih.gov/pubmed/28443358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517704507
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky